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Abstract: 
Mitochondria are a target of many drugs and environmental toxicants; 
however, how toxicant-induced mitochondrial dysfunction contributes to 
the progression of human disease remains poorly understood. To address 
this issue, in vivo assays capable of rapidly assessing mitochondrial 
function need to be developed. Here, using the model organism 
Caenorhabditis elegans, we describe how to rapidly assess the in vivo role 
of the electron transport chain, glycolysis or fatty acid oxidation, in energy 
metabolism following toxicant exposure, using a luciferase-expressing ATP-
reporter strain. Alterations in mitochondrial function subsequent to toxicant 
exposure are detected by depleting steady-state ATP levels with inhibitors 
of the mitochondrial electron transport chain, glycolysis, or fatty acid 
oxidation. Differential changes in ATP following short-term inhibitor 
exposure indicate toxicant-induced alterations at the site of inhibition. 
Because a microplate reader is the only major piece of equipment required, 
this is a highly accessible protocol for studying toxicant-induced 
mitochondrial dysfunction in vivo.  
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96-well plate Layout **Numerical GFP values (lower outline) in A1 correspond to the labels in A1 (i.e. A1=EPA H2O=53144).
1 2 3
A EPA H2O EPA H2O EPA H2O
B 20uM Rotenone 20uM Rotenone 20uM Rotenone
C 100uM Antimycin A 100uM Antimycin A 100uM Antimycin A
D 0.5mM azide 0.5mM azide 0.5mM azide
E 20uM DCCD 20uM DCCD 20uM DCCD
F 10uM FCCP 10uM FCCP 10uM FCCP
G 100uM Perhexiline 100uM Perhexiline 100uM Perhexiline
H BLANK BLANK BLANK
96-well plate Layout
1 2 3
A 53144 54622 46656
B 36688 41814 46441
C 35725 27948 34129
D 41386 35435 40984
E 43275 40468 36857
F 39080 41755 50130
G 37506 41891 42920
H 8470 8769 8895
TREATMENT GFP Blank Corrected GFP
EPA H2O 53144 44383.25
EPA H2O 54622 45861.25
EPA H2O 46656 37895.25
EPA H2O 47006 38245.25
1% DMSO 50321 41560.25
1% DMSO 55464 46703.25
1% DMSO 58244 49483.25
1% DMSO 50957 42196.25
10uM Rotenone 33379 24618.25
10uM Rotenone 43788 35027.25
10uM Rotenone 39449 30688.25
10uM Rotenone 36304 27543.25
20uM Rotenone 36688 27927.25
20uM Rotenone 41814 33053.25
20uM Rotenone 46441 37680.25
20uM Rotenone 39808 31047.25
1mM TTFA 41014 32253.25
1mM TTFA 49201 40440.25
1mM TTFA 48271 39510.25
1mM TTFA 58729 49968.25
50uM Antimycin A 48014 39253.25
50uM Antimycin A 52760 43999.25
50uM Antimycin A 52199 43438.25
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50uM Antimycin A 36526 27765.25
100uM Antimycin A 35725 26964.25
100uM Antimycin A 27948 19187.25
100uM Antimycin A 34129 25368.25
100uM Antimycin A 45799 37038.25
0.1mM azide 44863 36102.25
0.1mM azide 33847 25086.25
0.1mM azide 55980 47219.25
0.1mM azide 50725 41964.25
0.25mM azide 45507 36746.25
0.25mM azide 41603 32842.25
0.25mM azide 35321 26560.25
0.25mM azide 37448 28687.25
0.5mM azide 41386 32625.25
0.5mM azide 35435 26674.25
0.5mM azide 40984 32223.25
0.5mM azide 42634 33873.25
1.0mM azide 35703 26942.25
1.0mM azide 40804 32043.25
1.0mM azide 38885 30124.25
1.0mM azide 46117 37356.25
2.5mM azide 35354 26593.25
2.5mM azide 29877 21116.25
2.5mM azide 33552 24791.25
2.5mM azide 39901 31140.25
20uM DCCD 43275 34514.25
20uM DCCD 40468 31707.25
20uM DCCD 36857 28096.25
20uM DCCD 38683 29922.25
30uM DCCD 44007 35246.25
30uM DCCD 43659 34898.25
30uM DCCD 43804 35043.25
30uM DCCD 45695 36934.25
25uM FCCP 41545 32784.25
25uM FCCP 34741 25980.25
25uM FCCP 38030 29269.25
25uM FCCP 40877 32116.25
10uM FCCP 39080 30319.25
10uM FCCP 41755 32994.25
10uM FCCP 50130 41369.25
10uM FCCP 34880 26119.25
25uM Perhexiline 40236 31475.25
25uM Perhexiline 38514 29753.25
25uM Perhexiline 56140 47379.25
25uM Perhexiline 55708 46947.25
50uM Perhexiline 45828 37067.25
50uM Perhexiline 56348 47587.25
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50uM Perhexiline 54484 45723.25
50uM Perhexiline 49267 40506.25
100uM Perhexiline 37506 28745.25
100uM Perhexiline 41891 33130.25
100uM Perhexiline 42920 34159.25
100uM Perhexiline 40708 31947.25
BLANK 8470
BLANK 8769
BLANK 8895
BLANK 8909
Avg. Blank 8760.75
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**Numerical GFP values (lower outline) in A1 correspond to the labels in A1 (i.e. A1=EPA H2O=53144).
4 5 6 7 8
EPA H2O 1% DMSO 1% DMSO 1% DMSO 1% DMSO
20uM Rotenone 1mM TTFA 1mM TTFA 1mM TTFA 1mM TTFA
100uM Antimycin A 0.1mM azide 0.1mM azide 0.1mM azide 0.1mM azide
0.5mM azide 1.0mM azide 1.0mM azide 1.0mM azide 1.0mM azide
20uM DCCD 30uM DCCD 30uM DCCD 30uM DCCD 30uM DCCD
10uM FCCP 25uM Perhexiline 25uM Perhexiline 25uM Perhexiline 25uM Perhexiline
100uM Perhexiline
BLANK
4 5 6 7 8
47006 50321 55464 58244 50957
39808 41014 49201 48271 58729
45799 44863 33847 55980 50725
42634 35703 40804 38885 46117
38683 44007 43659 43804 45695
34880 40236 38514 56140 55708
40708     
8909     
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9 10 11 12
10uM Rotenone 10uM Rotenone 10uM Rotenone 10uM Rotenone
50uM Antimycin A 50uM Antimycin A 50uM Antimycin A 50uM Antimycin A
0.25mM azide 0.25mM azide 0.25mM azide 0.25mM azide
2.5mM azide 2.5mM azide 2.5mM azide 2.5mM azide
25uM FCCP 25uM FCCP 25uM FCCP 25uM FCCP
50uM Perhexiline 50uM Perhexiline 50uM Perhexiline 50uM Perhexiline
9 10 11 12
33379 43788 39449 36304
48014 52760 52199 36526
45507 41603 35321 37448
35354 29877 33552 39901
41545 34741 38030 40877
45828 56348 54484 49267
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Well Treatment Luminescence Blank Corrected Luminescence
A01 EPA H2O 95879 95693
A02 EPA H2O 87098 86912
A03 EPA H2O 65358 65172
A04 EPA H2O 75069 74883
A05 1% DMSO 75934 75748
A06 1% DMSO 89019 88833
A07 1% DMSO 84544 84358
A08 1% DMSO 83279 83093
A09 10uM Rotenone 25677 25491
A10 10uM Rotenone 36228 36042
A11 10uM Rotenone 28115 27929
A12 10uM Rotenone 27079 26893
B01 20uM Rotenone 28325 28139
B02 20uM Rotenone 23191 23005
B03 20uM Rotenone 34175 33989
B04 20uM Rotenone 26808 26622
B05 1mM TTFA 25938 25752
B06 1mM TTFA 32949 32763
B07 1mM TTFA 33612 33426
B08 1mM TTFA 45100 44914
B09 50uM Antimycin A 38080 37894
B10 50uM Antimycin A 42191 42005
B11 50uM Antimycin A 44775 44589
B12 50uM Antimycin A 28906 28720
C01 100uM Antimycin A 22706 22520
C02 100uM Antimycin A 19517 19331
C03 100uM Antimycin A 22945 22759
C04 100uM Antimycin A 27754 27568
C05 0.1mM azide 39487 39301
C06 0.1mM azide 30461 30275
C07 0.1mM azide 46714 46528
C08 0.1mM azide 43911 43725
C09 0.25mM azide 25582 25396
C10 0.25mM azide 26019 25833
C11 0.25mM azide 19749 19563
C12 0.25mM azide 24233 24047
D01 0.5mM azide 16638 16452
D02 0.5mM azide 18501 18315
D03 0.5mM azide 15294 15108
D04 0.5mM azide 22737 22551
D05 1.0mM azide 8364 8178
D06 1.0mM azide 7135 6949
D07 1.0mM azide 7555 7369
D08 1.0mM azide 8973 8787
D09 2.5mM azide 5003 4817
D10 2.5mM azide 2994 2808
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D11 2.5mM azide 5229 5043
D12 2.5mM azide 4194 4008
E01 20uM DCCD 26207 26021
E02 20uM DCCD 21607 21421
E03 20uM DCCD 20212 20026
E04 20uM DCCD 17001 16815
E05 30uM DCCD 8813 8627
E06 30uM DCCD 12410 12224
E07 30uM DCCD 7001 6815
E08 30uM DCCD 9204 9018
E09 25uM FCCP 27633 27447
E10 25uM FCCP 27080 26894
E11 25uM FCCP 30338 30152
E12 25uM FCCP 31714 31528
F01 10uM FCCP 26352 26166
F02 10uM FCCP 40644 40458
F03 10uM FCCP 47692 47506
F04 10uM FCCP 30568 30382
F05 25uM Perhexiline 64496 64310
F06 25uM Perhexiline 54201 54015
F07 25uM Perhexiline 84419 84233
F08 25uM Perhexiline 76679 76493
F09 50uM Perhexiline 65417 65231
F10 50uM Perhexiline 85760 85574
F11 50uM Perhexiline 80121 79935
F12 50uM Perhexiline 78934 78748
G01 100uM Perhexiline 69763 69577
G02 100uM Perhexiline 68426 68240
G03 100uM Perhexiline 78677 78491
G04 100uM Perhexiline 73089 72903
H01 BLANK 170
H02 BLANK 179
H03 BLANK 196
H04 BLANK 198
Avg. Blank 186
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Treatment GFP Luminescence Avg. GFP Normalization Factor ATP
EPA H2O 44383.25 95693 34494.01 1.286694297 74371.2
EPA H2O 45861.25 86912 1.329542312 65369.9
EPA H2O 37895.25 65172 1.098603686 59322.6
EPA H2O 38245.25 74883 1.108750374 67538.2
1% DMSO 41560.25 75748 1.204854008 62869
1% DMSO 46703.25 88833 1.353952345 65610.1
1% DMSO 49483.25 84358 1.434546041 58804.7
1% DMSO 42196.25 83093 1.22329199 67925.7
10uM Rotenone 24618.25 25491 0.713696313 35716.9
10uM Rotenone 35027.25 36042 1.015458823 35493.3
10uM Rotenone 30688.25 27929 0.889668878 31392.6
10uM Rotenone 27543.25 26893 0.798493636 33679.7
20uM Rotenone 27927.25 28139 0.809626003 34755.6
20uM Rotenone 33053.25 23005 0.958231501 24007.8
20uM Rotenone 37680.25 33989 1.09237072 31114.9
20uM Rotenone 31047.25 26622 0.900076482 29577.5
1mM TTFA 32253.25 25752 0.93503907 27541.1
1mM TTFA 40440.25 32763 1.172384605 27945.6
1mM TTFA 39510.25 33426 1.145423405 29182.2
1mM TTFA 49968.25 44914 1.448606452 31005
50uM Antimycin A 39253.25 37894 1.137972837 33299.6
50uM Antimycin A 43999.25 42005 1.27556193 32930.6
50uM Antimycin A 43438.25 44589 1.259298238 35407.8
50uM Antimycin A 27765.25 28720 0.804929536 35680.1
100uM Antimycin A 26964.25 22520 0.781708115 28808.7
100uM Antimycin A 19187.25 19331 0.556248701 34752.4
100uM Antimycin A 25368.25 22759 0.735439216 30946.1
100uM Antimycin A 37038.25 27568 1.073758795 25674.3
0.1mM azide 36102.25 39301 1.046623651 37550.3
0.1mM azide 25086.25 30275 0.727263884 41628.6
0.1mM azide 47219.25 46528 1.368911463 33989
0.1mM azide 41964.25 43725 1.216566185 35941.3
0.25mM azide 36746.25 25396 1.065293558 23839.4
0.25mM azide 32842.25 25833 0.952114497 27132.2
0.25mM azide 26560.25 19563 0.769995938 25406.6
0.25mM azide 28687.25 24047 0.831658812 28914.5
0.5mM azide 32625.25 16452 0.945823551 17394.4
0.5mM azide 26674.25 18315 0.773300859 23684.2
0.5mM azide 32223.25 15108 0.934169354 16172.7
0.5mM azide 33873.25 22551 0.982003742 22964.3
1.0mM azide 26942.25 8178 0.781070323 10470.2
1.0mM azide 32043.25 6949 0.928951057 7480.48
1.0mM azide 30124.25 7369 0.873318215 8437.93
1.0mM azide 37356.25 8787 1.082977786 8113.74
2.5mM azide 26593.25 4817 0.770952625 6248.11
2.5mM azide 21116.25 2808 0.612171449 4586.95
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2.5mM azide 24791.25 5043 0.718711676 7016.72
2.5mM azide 31140.25 4008 0.902772602 4439.66
20uM DCCD 34514.25 26021 1.000586677 26005.7
20uM DCCD 31707.25 21421 0.919210237 23303.7
20uM DCCD 28096.25 20026 0.814525404 24586.1
20uM DCCD 29922.25 16815 0.867462126 19384.1
30uM DCCD 35246.25 8627 1.021807751 8442.88
30uM DCCD 34898.25 12224 1.011719044 12082.4
30uM DCCD 35043.25 6815 1.015922672 6708.19
30uM DCCD 36934.25 9018 1.070743779 8422.18
25uM FCCP 32784.25 27447 0.950433046 28878.4
25uM FCCP 25980.25 26894 0.753181425 35707.2
25uM FCCP 29269.25 30152 0.848531305 35534.3
25uM FCCP 32116.25 31528 0.931067367 33862.2
10uM FCCP 30319.25 26166 0.87897137 29768.9
10uM FCCP 32994.25 40458 0.956521059 42297
10uM FCCP 41369.25 47506 1.199316815 39610.9
10uM FCCP 26119.25 30382 0.75721111 40123.6
25uM Perhexiline 31475.25 64310 0.912484432 70477.9
25uM Perhexiline 29753.25 54015 0.862562725 62621.5
25uM Perhexiline 47379.25 84233 1.373549949 61325
25uM Perhexiline 46947.25 76493 1.361026036 56202.5
50uM Perhexiline 37067.25 65231 1.074599521 60702.6
50uM Perhexiline 47587.25 85574 1.379579981 62029
50uM Perhexiline 45723.25 79935 1.325541618 60303.7
50uM Perhexiline 40506.25 78748 1.174297981 67059.6
100uM Perhexiline 28745.25 69577 0.833340263 83491.7
100uM Perhexiline 33130.25 68240 0.960463772 71049
100uM Perhexiline 34159.25 78491 0.990295036 79260.2
100uM Perhexiline 31947.25 72903 0.926167966 78714.7
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Treatment Avg. ATP % Control ATP
EPA H2O 66650.46
1% DMSO 63802.39 95.73
10uM Rotenone 34070.61 53.40
20uM Rotenone 29863.93 46.81
1mM TTFA 28918.47 45.33
50uM Antimycin A 34329.53 53.81
100uM Antimycin A 30045.39 47.09
0.1mM azide 37277.32 55.93
0.25mM azide 26323.20 39.49
0.5mM azide 20053.87 30.09
1.0mM azide 8625.60 12.94
2.5mM azide 5572.86 8.36
20uM DCCD 23319.92 36.55
30uM DCCD 8913.91 13.97
25uM FCCP 33495.54 52.50
10uM FCCP 37950.09 59.48
25uM Perhexiline 62656.73 98.20
50uM Perhexiline 62523.73 98.00
100uM Perhexiline 78128.90 122.45
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In vivo Determination of Mitochondrial Function using Luciferase-Expressing 
Caenorhabditis elegans: Contribution of Oxidative Phosphorylation, Glycolysis, 
and Fatty Acid Oxidation to Toxicant-Induced dysfunction. 
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[*Au: CP template requires that the protocol be described in stepwise guidelines. Please 
number the steps in each protocol.] 
ABSTRACT  
 
Mitochondria are a target of many drugs and environmental toxicants; however, how toxicant-
induced mitochondrial dysfunction contributes to the progression of human disease remains 
poorly understood. To address this issue, in vivo assays capable of rapidly assessing 
mitochondrial function need to be developed. Here, using the model organism Caenorhabditis 
elegans, we describe how to rapidly assess the in vivo role of the electron transport chain, 
glycolysis or fatty acid oxidation, in energy metabolism following toxicant exposure, using a 
luciferase-expressing ATP-reporter strain. Alterations in mitochondrial function subsequent to 
toxicant exposure are detected by depleting steady-state ATP levels with inhibitors of the 
mitochondrial electron transport chain, glycolysis, or fatty acid oxidation. Differential changes 
in ATP following short-term inhibitor exposure indicate toxicant-induced alterations at the site 
of inhibition. Because a microplate reader is the only major piece of equipment required, this is 
a highly accessible protocol for studying toxicant-induced mitochondrial dysfunction in vivo.  
Keywords: Caenorhabditis elegans, mitochondrial toxicity, PE255, PE327, glycolysis, oxidative 
phosphorylation, fatty acid oxidation 
 
 
 
 
 
 
INTRODUCTION 
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 Mitochondria are best known for the role they play in ATP production via oxidative 
phosphorylation; however, mitochondria also play crucial roles in apoptosis (Susin et al., 1999), 
calcium homeostasis (Duchen, 2000) and retrograde signaling (Liu and Butow, 2006), thus 
playing diverse roles in cellular and organismal health. Mitochondrial dysfunction is causative 
and/or associated with numerous human diseases, including cancer (Baysal et al., 2000; 
Wallace, 2012; Yan et al., 2009), metabolic syndrome (Bugger, 2008), and various neurological 
disorders (Beal, 2005; Lin and Beal, 2006). Furthermore, growing evidence has demonstrated 
that mitochondria are an important target of many drugs (e.g. antibiotics and nucleoside 
reverse transcriptase inhibitors) (Dykens and Will, 2007; Guan, 2011; Poirier et al., 2015) and 
environmental toxicants (e.g. polycyclic aromatic hydrocarbons  and pesticides) (Backer and 
Weinstein, 1980; Meyer et al., 2013; Tanner et al., 2011), and toxicant-induced mitochondrial 
dysfunction has been implicated in many diseases, including cancer and neurodegeneration 
(Robey et al., 2015; Tanner et al., 2011; Zhao et al., 2014).  
Because mitochondrial function is dependent upon cellular context and environmental cues 
(Chan, 2012; McBride et al., 2006), it is critical to develop assays capable of rapidly assessing 
mitochondrial function, in vivo, following toxicant exposure. A short lifecycle (2-3 weeks), high 
reproductive rate (~300 offspring per gravid adult), and highly conserved mitochondrial biology 
(Tsang and Lemire, 2003) and biochemical pathways (Braeckman et al., 2009) contribute to the 
utility of the model organism Caenorhabditis elegans for studying toxicant-induced 
mitochondrial dysfunction. Furthermore, significant overlap between the activities of Toxcast 
phase I and II libraries have recently been described between nematodes and zebrafish, further 
validating C. elegans as an important non-mammalian model (Boyd et al., 2015). Currently, 
mitochondrial respiration in C. elegans can be measured via low-throughput Clark type 
electrodes (Braeckman et al., 2002), or with the higher-throughput, but more expensive 
Seahorse XF
e
 Bioanalyzer (Luz et al., 2015a; Luz et al., 2015b). Additionally, small metabolites, 
such as ATP, pyruvate, or NADH can be extracted from nematodes and used to assess 
mitochondrial health (Brys et al., 2010; Krijgsveld et al., 2003); however, this is a time 
consuming process. Alternatively, transgenic, firefly luciferase-expressing PE255 nematodes can 
be used to rapidly assess steady-state ATP levels in vivo (Lagido et al., 2009; Lagido et al., 2008). 
This transgenic model has proven valuable to environmental toxicologists, and has been used to 
study the effects of  heavy metals and 3,5-dichlorophenol (Lagido et al., 2009; Lagido et al., 
2001), 5-fluoro-2-deoxyuridine (Rooney et al., 2014), sewage sludge extract (McLaggan et al., 
2012), the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(Bodhicharla et al., 2014), and ultraviolet C radiation (Bess et al., 2012; Bess et al., 2013; Leung 
et al., 2013) on steady-state ATP-levels, and has more recently been used to track nematode 
development (Olmedo et al., 2015), and screen drug-libraries (Lagido et al., 2015). 
Here, using PE255 luciferase-expressing nematodes and well-established inhibitors of the 
mitochondrial electron transport chain (ETC), glycolysis, and fatty acid oxidation (FAO) we 
describe a novel method that can be used to rapidly screen for alterations in mitochondrial 
energy metabolism following drug or toxicant exposure. Short-term incubation with these 
inhibitors depletes steady-state ATP levels. Thus, differential depletion of ATP in toxicant 
exposed nematodes in response to inhibitors indicates the relative contribution of the targeted 
cellular process to energy metabolism. Using this approach we recently demonstrated induction 
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of a Warburg-like effect in arsenite exposed PE255 glp-4 nematodes (Luz et al., Submitted), 
which was confirmed via Seahorse XF
e
 and small metabolite analysis, thus further 
demonstrating this protocol’s utility in detecting toxicant-induced mitochondrial dysfunction. 
 
BASIC PROTOCOL 1 
 
Luciferase-based in vivo assessment of mitochondrial energy metabolism in C. elegans 
Here, using the PE255 ATP reporter strain (Lagido et al., 2015; Lagido et al., 2008), and the well-
known pharmacological inhibitors rotenone (complex I), thenoyltrifluoroacetone (TTFA, 
complex II), antimycin A (complex III), sodium azide (complex IV), dicyclohexylcarbodiimide 
(DCCD, ATP synthase), carbonyl cyanide-p-trifluoromethoxyphenylhydrazon (FCCP, 
mitochondrial uncoupler), perhexiline (fatty acid oxidation (FAO)), and 2-deoxy-D-glucose (2-
DG, glycolysis)) we outline how to rapidly assess mitochondrial energy metabolism following 
toxicant exposure. All of these inhibitors have previously been demonstrated to work in C. 
elegans (Luz et al., 2015b; Schulz et al., 2007; Taylor et al., 2013; Zubovych et al., 2010). Short-
term (1.0 or 4.5 hour) incubation with inhibitors results in changes in steady-state ATP levels. 
Thus, altered function at the site of inhibition is detected through differential depletion of 
steady-state ATP levels. For example, the magnitude of ATP depletion following inhibition of 
ETC complex I with rotenone will be less than in toxicant exposed relative to unexposed 
nematodes if toxicant exposure has the effect of reducing complex I activity. This is because 
complex I is already contributing less to maintenance of steady-state ATP levels. Alternatively, 
the magnitude of ATP depletion will be greater in toxicant exposed nematodes if toxicant 
exposure is increasing activity of complex I. Figure 1 details the main principles of this assay. 
 
  
Materials: 
 
REAGENTS: 
OP50 seeded K-agar plates (see Support Protocol 1) 
Synchronous populations of L1 PE255 nematodes (see Support Protocol 2; Transgenic (PE255)  
N2 (wild type) and PE327 glp-4 (bn2) nematodes available through the Caenorhabditis Genetics 
Center, University of Minnesota) 
K-medium (see recipe) 
Inhibitor stocks (Table 1 outlines all required inhibitors, as well as storage conditions) 
Dimethylsulfoxide (DMSO) 
Unbuffered EPA H2O (see recipe) 
0.1% (v/v) Triton X-100 (diluted in ddH2O; store at room temperature indefinitely) 
Glass microscope slides 
Disposable reagent reservoirs 
Multi-channel pipette (capable of pipetting 20-200µl) 
White 96-well plates without lids 
Luminescence buffer (see recipe) 
EQUIPMENT: 
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Incubator (capable of maintaining temperatures in the range of 15-25°C) 
Centrifuge (e.g. Beckman Coulter equipped for 15mL tubes) 
Dissecting light microscope 
Horizontal vortexer (e.g. Eppendorf MixMate PCR 96) 
Orbital shaker 
Microplate reader (FLUOstar OPTIMA, BMG Labtech) equipped with luminescence optic, 502nm                                             
    emissions filter, and 485 nm excitation filter 
 
Nematode culturing [*Au: This seems like a supporting protocol] 
Nematodes are cultured on k-agar plates seeded with E. coli strain OP50 as previously 
described (Stiernagle, 1999).  
Using a sterile Pasteur pipet transfer age-synchronous L1 PE255 nematodes, obtained from 
sodium hydroxide bleach treatment (see Support Protocol 2), to an OP50 seeded k-agar plate 
(see Support Protocol 1). Culture the nematodes until the appropriate life stage for toxicant or 
drug exposure is reached. 
 
Both PE255 glp4 (strain PE327) and PE255 N2 (wild type) nematodes are available for purchase 
for a nominal fee, through the National Institutes of Health-supported Caenorhabditis Genetics 
Center (CGC, University of Minnesota). 
 
This assay was originally developed using germline-deficient, PE255 glp-4 (bn2) nematodes, 
which are maintained at the permissive temperature of 15°C. Shifting glp-4 nematodes to the 
restrictive temperature, 25°C, results in sterile, germ cell free nematodes (Beanan and Strome, 
1992). However, we have successfully used most of the concentrations of inhibitors outlined in 
this assay (see Table 1) with both L4 and 8 day old adult PE255 N2 nematodes, which are 
maintained at 20°C. 
Toxicant or Drug Exposure 
This assay can be used to assess mitochondrial function following toxicant or drug exposure. 
The precise length of exposure is at the discretion of the experimenter. However, if using PE255 
N2 nematodes we recommend assaying prior to, or after the reproduction period, as 
reproduction will add variability to experiments. Nematodes can be exposed in liquid or on 
agar; however, liquid exposures can facilitate drug uptake in nematodes (Zheng et al., 2013). 
Finally, be sure to thoroughly rinse toxicant exposed nematodes 3-4 times with 15ml k-medium 
to remove excess toxicant prior performing this assay. 
Preparation of Inhibitors [*Au: This seems like it belongs either in a Reagents & Solutions 
section or as supporting protocol. Isn’t this described in the Table? If this is the same as what 
is described in table 1 then this section is redundant and can only be referenced as Table 1.] 
 
Prepare stocks of 2mM rotenone, 100mM TTFA, 15mM antimycin A, 2mM sodium azide, 2mM 
DCCD, 2.5mM FCCP, 10mM perhexiline, and 400mM 2-DG in either 100% unbuffered EPA water 
or DMSO as outlined in Table 1. To minimize freeze/thawing, stocks can be stored in 30µl 
aliquots at either 4°C or -20°C (see Table 1). 
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Titrations of each drug were performed in sterile young adult (cultured on agar for 72h at 25°C) 
PE255 glp-4 nematodes (Supplementary Figures 1-8). Concentrations of each ETC inhibitor that 
result in a 40-60% depletion of ATP after a one hour exposure were then chosen.  
 
A 4.5 hour exposure to 50mM 2-DG gave the most consistent reduction in luminescence in the 
context of arsenite exposure (Luz et al., Submitted), thus was chosen for all future experiments. 
 
A 1 hour exposure to 100µM perhexiline increased nematode luminescence (~25%) in PE255 glp-
4-deficient nematodes (Supplemental Figure 8), and thus was chosen for all future experiments. 
Our rationale for this result is detailed in the Anticipated Results, perhexiline section. 
Dilute inhibitor stocks with unbuffered EPA H2O to the appropriate 8X working concentrations 
as outlined in Table 1. 
 
All inhibitors are dissolved in either DMSO or unbuffered EPA water. 8X Working stocks contain 
zero or 8% DMSO, such that when 12.5µl of the 8X working stock is pipetted into a well of a 
white 96-well plate (containing 50 nematodes in 87.5µl unbuffered EPA H2O) the inhibitor is 
diluted to its final, 1X, working concentration in 1% DMSO. A one hour exposure to 1% DMSO 
does not significantly affect ATP levels in young adult PE255 glp-4, or L4 or 8 day old PE255 N2 
nematodes (Supplemental Figure 1, 9). 
Preparation of nematodes for inhibitor exposure 
Remove PE255 nematodes from the incubator. If nematodes are being exposed to a drug or 
toxicant (either on agar or in liquid), be sure to rinse the nematodes thoroughly to remove 
excess toxicant.  
 
Excess toxicant can be removed by transferring toxicant exposed nematodes to a new 15ml 
centrifuge tube, and resuspending them in 15ml unbuffered EPA H2O. Nematodes can then be 
pelleted by centrifuging at 2200 RCF for 2 minutes at room temperature. The supernatant can 
then be discarded in accord with your university’s guidelines. This process should then be 
repeated an additional 2-3 times to ensure toxicant is completely removed through dilution.  
 
Resuspend the nematodes to a final concentration of 1.0±0.2 nematodes per microliter in 
unbuffered EPA H2O. 
The minimal acceptable concentration is 0.6 nematodes per microliter, as this concentration 
results in approximately 50 nematodes per 87.5µl; however, we recommend diluting nematodes 
to a concentration of 0.8-1.2 nematodes per microliter for all samples to minimize variation.  
To estimate the number of nematodes per microliter, trim the tip of a 200µl pipette tip, and 
pipette 20µl of 0.1% Triton X-100 up and down. The triton prevents worm loss due to sticking. 
Pipet four 20µl drops of nematodes onto a glass slide and count the number of nematodes per 
20µl on a dissecting light microscope. Be sure to use a new, triton rinsed tip for each drop, and 
invert the centrifuge tube several times between counts to resuspend the nematodes.  
 Calculate the volume required to obtain 50 nematodes. 
For example, if your concentration of nematodes is 1.0 nematode per microliter, you will pipette 
50µl into each well of the 96-well plate to achieve 50 nematodes per well. 
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Pour 5ml 0.1% Triton X-100, 5ml unbuffered EPA H2O, and the nematode suspension into three 
separate, new, 25ml disposable reagent reservoirs. 
Using a 200µl multi-channel pipette, pipet 50 nematodes into the appropriate wells of a white 
96-well plate.  
Prior to pipetting nematodes into a white 96-well plate trim the pipet tips with scissors to 
increase each tips circumference, which allows large adult nematodes to be pipetted without 
injury. Then rinse the pipette tips with 0.1% Triton X-100 by pipetting up and down, which 
prevents nematode loss due to sticking. Nematodes can then be re-suspended in the reagent 
reservoir prior to their addition to the 96-well plate by pipetting up and down 3-4 times with the 
multi-channel pipette. Use new, trimmed, triton-rinsed tips each time you resuspend and 
transfer nematodes.  
Figure 2 illustrates how a 96-well plate may be set up for an experiment containing two 
experimental groups. For example, each group (i.e. control and toxicant exposed) is pipetted 
into 4 wells of a 96-well plate for each inhibitor or control (i.e. EPA H2O or 1% DMSO) used. We 
recommend setting up 2 plates, one for the one hour inhibitor exposure (rotenone, TTFA, 
antimycin A, azide, DCCD, FCCP, perhexiline), and one for the 4.5 hour inhibitor exposure (2-DG; 
not shown, but can be setup in a manner similar to Figure 2. Note that 2-DG does not require a 
1% DMSO control, as it is dissolved in EPA H2O). 
Using a multi-channel pipette bring the volume in each well to 87.5µl with unbuffered EPA H2O. 
 EPA H2O controls (i.e. nematodes unexposed to inhibitors or DMSO) and blank wells can be 
brought to a final volume of 100µl with unbuffered EPA H2O. 
Using a 20µl pipette, add 12.5µl of each 8X inhibitor (prepared in steps 2-3 and outlined in 
Table 1) to the appropriate wells. Figure 2 outlines how nematodes can be loaded into a 96 well 
plate; however, this will vary depending upon the number of exposure groups, and inhibitors 
chosen for each experiment (outlined in Figure 2). 
It should take no longer than 3-4 minutes to load all of the inhibitors for each plate. This is 
important, because the inhibitor incubation period is only 60 minutes (for ETC, and FAO 
inhibitors); thus, a longer loading period will introduce variability into the assay. If necessary, 
samples can be divided onto multiple 96-well plates to limit the amount of time it takes to load 
all of the inhibitors. However, be sure to include the appropriate EPA H2O and DMSO controls, as 
well as blanks for each plate. The addition of inhibitors should be staggered 15-20 minutes for 
each plate to avoid overlap on the plate reader. 
At minimum, two plates will be run. The first plate is designated for one hour inhibitor 
incubations (rotenone, TTFA, antimycin A, azide, DCCD, FCCP, perhexiline, EPA H2O and 1% 
DMSO controls), while the second plate is for the 4.5 hour inhibitor incubations (i.e. 2-DG, EPA 
H2O control). 
Vortex the white 96-well plate for 10 seconds at 1000 rpm using a horizontal vortexer after the 
final inhibitor has been added.  
Vortexing will help ensure that inhibitors are mixed and completely in solution. 
Place the 96-well plate on an orbital shaker at 20°C for 60 minutes or 4.5 hours depending upon 
which inhibitors are being tested. 
Measuring steady-state ATP levels 
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In the presence of ATP, firefly luciferase catalyzes the oxidation of luciferin to generate light. 
Thus, steady-state ATP levels can be determined in vivo by measuring light output, which is 
proportional to steady-state ATP levels in PE255 nematodes (Lagido et al., 2008). Nematode 
luminescence can be measured using a microplate reader equipped with a luminescence optic 
and filters capable of measuring GFP fluorescence (502nm emissions, 485nm excitation). Below 
we detail how to measure ATP in PE255 nematodes using a FLUOstar OPTIMA (BMG LABTECH) 
plate reader; however, precise instruction will vary depending upon the microplate reader 
model being used. A recent visual presentation of this assay is also available (Lagido et al., 
2015). 
 
Prepare the luminescence buffer (see recipe) 15 minutes prior to the end of the incubation 
period. [*Au: This seems like a reagents & solutions section] 
 
Luminescence buffer can be prepared in 15ml centrifuge tube covered in foil to protect light-
sensitive luciferin. 
Turn on the plate reader and open the OPTIMA software 15 minutes before the incubation 
period has ended. Prepare the plate reader for measuring GFP fluorescence. 
PE255 nematodes express a firefly luciferase – GFP fusion protein. Thus by normalizing each 
wells luminescence reading to GFP, you can account for overall enzyme content, which will help 
to normalize each well for slight discrepancies in nematode size and overall nematode counts.  
Under reader configuration, select the fluorescence optic. 
Select test setup. Click on fluorescence intensity, and make a new program for measuring GFP. 
Name (i.e. PE255::GFP) and save the program for future use. Guidelines for preparing the 
program are outlined below. 
Plate type: (fill in with the appropriate plate brand) 
Optic used: Top 
Excitation filter: 485nm 
Emission filter: 502nm 
Position delay (s): 0.2 
Kinetic window: 1 
Number of cycles: 1 
Measurement start time (s): 0.0 
Number of flashes: 10 
 
Open the newly designed program. Under the Layout tab select the appropriate sample 
containing wells. Click Okay. 
Approximately 10 minutes before the incubation period has ended, insert the 96-well plate into 
the microplate reader. Click on measure and select the appropriate protocol for measuring GFP. 
Name the current run in the pop-up menu.  
Click on the gain tab and highlight the entire plate. Click gain adjust. 
Gain adjusting the entire plate will identify the well with the highest GFP fluorescence, which 
will be used to normalize the entire plate. The raw gain value should be somewhere around 
58,000, although this may vary for other microplate reader models. 
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Click start measurement. When the measurement has finished exit the OPTIMA software. Turn 
off the plate reader. 
GFP measurements are automatically saved in the OPTIMA software. 
Carefully remove the fluorescence optic from the microplate reader and replace it with the 
luminescence optic. 
For more details see the plate reader’s user manual. 
Turn on the plate reader and open the OPTIMA software. Click on Reader Configuration and 
select luminescence optic. 
Prime the injector (if applicable) for luminescence buffer injection. First, insert the injector 
needle into a waste container (50ml centrifuge tube covered with foil) and the tubing into a 
50ml centrifuge tube containing 70% ethanol. Next, select the priming function and flush the 
injector needle with 2ml 70% ethanol, following by 2ml ddH2O, and finally prime the injector 
needle with 1.5ml of luminescence buffer.  
If your plate reader is not equipped with an injecting apparatus you can manually pipette the 
luminescence buffer into your 96-well plate using a multi-channel pipette and then read 
luminescence 3 minutes later. 
Remove the injector needle from the waste container and place it into the machine’s injection 
port. 
Select test setup. Click on luminescence intensity, and make a new program for measuring 
luminescence. Name (i.e. PE255-Luminescence) and save the program for future use. 
Guidelines for measuring luminescence are outlined below. 
Plate type: (fill in with the appropriate plate brand) 
Optic used: Top 
Gain: 3600 
Emission filter: lens 
Position delay (s): 0.2 
Shaking width (mm): 7 
Shaking mode: orbital 
Number of cycles: 2 
Cycle time (s): 180 
Measurement start time (s): 0.0 
Measurement interval time (s): 1.0 
Injector Setup 
Volume (µl): 50 
Pump used: 1 
Pump speed (µl/s): 420 
Pump syringe volume (ml): 0.5 
Injection cycle: 1 
Injection start time (s): 0.0 
 
Open the newly designed program. Under the layout tab select the appropriate sample 
containing wells. 
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Click on the injection tab. Make sure all sample containing wells are set to have 50µl of 
luminescence buffer injected. Click Okay. 
Click on Measure and select the appropriate protocol for measuring luminescence. Name the 
current run in the pop-up menu.  Click start. 
When the luminescence measurement finishes the results automatically save in the OPTMA 
software. 
When finished with the instrument, wash the injector tubing. First, remove the injector needle 
from the plate reader and place it into the waste container. Place the injector tubing into 
ddH2O, and rinse the tubing with 3ml ddH2O, followed by 3ml 70% ethanol. Finally, dry the 
injector tubing by back flushing 3ml into the waste container. 
Back flushing the injector pushes air through the line to dry it out; any remaining ethanol in the 
line should then evaporate. 
Open results in the OPTIMA Software. Blank correct each well’s GFP and luminescence values 
by subtracting the EPA H2O blank GFP and luminescence values, respectively. An example of 
how to normalize data is provided in Supplemental File 1. 
Each well’s blank-corrected luminescence can be divided by the corresponding blank-corrected 
GFP value. Alternatively, we generate normalization factors for each well by dividing each wells 
blank-subtracted GFP value by the average GFP value for the entire plate. Blank-corrected 
luminescence values can then be divided by the corresponding normalization factor as detailed 
in Supplemental File 1.  
Statistical Analysis 
Assuming normally distributed data (which has been our experience), assess the effects of each 
drug initially with a one-, two-, or three-way ANOVA, depending upon how many factors you 
have (i.e. time, strain, dose, etc.). If different developmental stages are compared, ATP levels 
may vary enough that logarithmic transformation of the data is necessary to permit comparison 
of exposure-or strain-related differences across ages. When warranted, post-hoc analysis can 
be performed. 
 
SUPPORT PROTOCOL 1  
Preparing OP50 seeded k-agar plates  
Nematodes are cultured on Escherichia coli OP50 seeded k-agar plates. The preparation of 
OP50 seeded K-agar plates has previously been described (Lewis and Fleming, 1995; Stiernagle, 
1999), and is briefly outlined below. 
Materials: 
Potassium chloride (KCl), 
Sodium chloride (NaCl) 
Bacto-peptone 
Bacto-agar 
1M Calcium chloride (CaCl2, dissolved in ddH2O and autoclaved) 
1M Magnesium sulfate (MgSO4, dissolved in ddH2O and autoclaved) 
10 mg/ml Cholesterol (dissolved in ethanol and filter sterilized) 
5mL 1.25 mg/ml Nystatin (dissolved in ethanol) 
LB broth (see recipe) 
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E. coli OP50 (which can be purchased from the Caenorhabditis Genetics Center, University of  
 Minnesota) 
 
Erlenmeyer flask (2L or larger) 
Magnetic spin bar 
Magnetic hot plate 
Autoclave tape 
Autoclave 
Serological pipette (25 or 50 mL) 
Motorized pipette aid (e.g. Drummond) 
Petri dishes (100 x 50mm) 
Inoculating loop 
37°C Shaking incubator  
Repeating pipette (e.g. Eppendorf) & 10 mL displacement tips 
Glass hockey stick spreaders 
Rotating pedestal 
Bunsen burner 
 
Pouring k-agar plates 
Weigh and add 2.36g potassium chloride, 3.0g sodium chloride, 2.5g bacto-peptone, and 20g 
bacto-agar to a 2L Erlenmeyer flask containing 1L ddH2O and a magnetic spin bar. Cover the 
flask with foil and add autoclave tape. 
 
Prior to autoclaving the agar can be mixed gently on a magnetic spin plate; however, this is not 
required, as autoclaving will dissolve all ingredients.  
 
Autoclave to sterilize. 
 
A 30 minute liquid cycle at 121°C and 17psi is sufficient for sterilization. 
 
Place sterilized k-agar on a magnetic spin plate with the spin bar turned on and let the agar cool 
to ≈55°C. 
 
Once cooled, add 1ml 1M CaCl2, 1ml 1M MgSO4, 1 ml 10 mg/ml cholesterol, and 5 ml 1.25 
mg/ml nystatin (dissolve in 100% EtOH) to the k-agar. 
 
The nystatin is an anti-fungal used to help prevent contamination. 
 
Using a 50 mL serological pipet, carefully pipette 17mL k-agar into a 100x50mm sterile petri 
dish. Gently swirl the agar to ensure the entire surface of the plate is covered. 
 
Caution! K-agar plates are easily contaminated. To minimize contamination risk use sterile 
technique. One liter of k-agar fills approximately 60 petri dishes. 
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Let the k-agar plates cool and solidify overnight (12-18 hours). 
 
Growing E. coli OP50 
 
Using sterile technique, inoculate 50mL sterile LB broth (see recipe) with E. coli OP50 using a 
sterile inoculating loop. 
 
Incubate the LB broth at 37°C, while shaking at 250 rpm, overnight (16 hours). 
 
Seeding K-agar plates with OP50 
 
Using sterile technique pipette 300µl of OP50 culture onto the center of each k-agar plate. 
 
We use a 10mL Eppendorf repeating pipettor, which minimizes the number of times that you 
will have to pipette directly from the OP50 culture, thus minimizing the risk of contamination. 
 
 Using a sterile glass hockey stick and a rotating pedestal spread the OP50 on the surface of the 
k-agar. 
 
To sterilize the glass hockey stick dip it in 70% ethanol, and then pass it through the flame of a 
bunsen burner and allow the ethanol to burn off. Re-sterilize the hockey stick every five plates. 
 
Let the OP50 seeded k-agar plates dry at room temperature (~48 hours). Dry OP50 plates can 
then be stored at 4°C for up to 3 months. 
 
SUPPORT PROTOCOL 2  
Age-synchronizing nematodes via sodium hypochlorite treatment 
Synchronous populations of L1 nematodes can be generated by treating gravid adult 
nematodes with sodium hypochlorite solution. Nematode eggs are resistant to sodium 
hypochlorite, while gravid adults are not, which allows for the isolation of eggs. Eggs are then 
allowed to hatch overnight (12-18 hours) in the absence of food, resulting in synchronous 
populations of L1 nematodes (Lewis and Fleming, 1995). Note that the timing may need to be 
reduced if using RNAi or crossing luciferase reporter strains with strains carrying mutations, 
because some genetic manipulations sensitize eggs to this treatment. 
Materials 
OP50 seeded k-agar plates (see Support Protocol 1) containing gravid adult nematodes 
K-medium (see recipe) 
70% ethanol 
15 mL Centrifuge tubes (e.g. Corning Falcon) 
Centrifuge (e.g. Beckman Coulter equipped for 15mL tubes) 
Glass hockey stick spreader 
Bunsen burner 
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Orbital shaker 
Pasteur pipette 
50ml cell culture flask 
Dissecting light microscope 
 
Using sterile k-medium wash gravid adult nematodes from the k-agar plate into a new 15 mL 
centrifuge tube. Pellet nematodes by centrifuging at 2200 RCF for 2 minutes at room 
temperature. Discard the supernatant. 
Pipette 2-3ml k-medium onto k-agar plate and gently loosen eggs from the surface of the agar 
using a sterile glass hockey stick spreader. Carefully pour the loosened eggs into the 15 ml 
centrifuge tube containing the gravid adult nematodes, and spin at 2200 RCF for 2 minutes. 
Discard the supernatant. 
Glass hockey stick spreaders can be sterilized by dipping them in 70% ethanol, and then passing 
them through the flame of a Bunsen burner, allowing the ethanol to burn off. 
Carefully add 10ml of sodium hydroxide bleach solution (see recipe) to the nematode pellet. 
Place the centrifuge tube on an orbital shaker in a 20°C incubator for 8 minutes. 
8 minutes is sufficient time for the sodium hydroxide bleach solution to disintegrate adult 
nematodes, but not eggs, allowing for the isolation of a large quantity of nematode eggs. After 
8 minutes, if adult nematodes remain, place the tube back on the orbital shaker for up to 2 
additional minutes. 
After 8 minutes, spin the centrifuge tube at 2200 RCF for 2 minutes, discard the supernatant, 
and resuspend the pelleted eggs in 15 ml k-medium.  
Take care not to disturb the egg pellet when removing the bleach solution; however, no more 
than 50-100µl of bleach solution should remain prior to resuspension in k-medium.  
Spin the resuspended eggs for an additional 2 minutes at 2200 RCF. Discard all but 0.5-1.0ml of 
the supernatant. 
Using a sterile glass Pasteur pipette, resuspend the pelleted eggs, and transfer them to a sterile 
50ml cell culture flask containing 8ml complete k-medium (see recipe). 
Incubate the flask overnight (12-18 hours) on an orbital shaker at 20°C to obtain a synchronous 
population of L1 nematodes. 
Under a dissecting light microscope check to make sure the majority of the eggs have hatched. 
Pour the L1 nematodes into a sterile 15 mL centrifuge tube, and centrifuge at 2200 RCF for 2 
minutes. Discard the supernatant. 
Transfer the nematodes to an OP50 seeded k-agar plate (see support protocol 1) using a 
Pasteur pipette and incubate the nematodes at the appropriate temperature until the desired 
life stage is reached. 
REAGENTS AND SOLUTIONS 
Complete k-medium 
 150µl 1M calcium chloride (CaCl2; sterilized via autoclave) 
 150µl 1M magnesium sulfate (MgSO4; sterilized via autoclave) 
25µl 10mg/ml cholesterol (dissolve in 100% ethanol and filter sterilize) 
50mL sterile k-medium 
Store at room temperature for up to one week 
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K-medium 
 2.36g Potassium chloride (KCl) 
 3g Sodium chloride (NaCl) 
 1L ddH2O 
 Autoclave to sterilize 
Store at room temperature, indefinitely, under sterile conditions 
 
LB broth 
 0.5g Tryptone 
 0.25g Yeast extract 
 0.5g Sodium chloride (NaCl) 
 50mL ddH2O 
 Autoclave to sterilize 
 Store at room temperature, indefinitely, under sterile conditions 
 
Luminescence Buffer 
6.925ml 0.2M Na2PO4 (store at room temperature) 
3.075ml 0.1M Citric acid (store at room temperature) 
100µl DMSO 
100µl 5% Triton X-100 (diluted in ddH2O) 
100µl 10mM Luciferin salt (dissolved in ddH2O; store in 100µl aliquots at -20°C; protect  from 
light) 
 Make fresh prior to ATP measurements 
 
Sodium hydroxide bleach solution 
6mL Clorox bleach (non-germicidal, regular bleach*, 8.25% sodium hypochlorite) 
 5 Sodium hydroxide pellets (NaOH; Avantor Performance Materials) 
 44mL ddH20 
 Shake until NaOH pellets are completely dissolved 
 Each pellet weighs ~89mg. 
Store at room temperature for up to 3 days. 
*It is important to use non-germicidal bleach, as some bleaches contain germicides that are 
toxic to nematodes. 
 
Unbuffered EPA water (Weber, 1991) 
 60mg Magnesium sulfate (MgSO4 · 7 H2O) 
 60mg Calcium sulfate (CaSO4 · 2 H2O) 
 4mg Potassium chloride (KCl) 
 1L ddH2O 
 Store at room temperature, indefinitely, under sterile conditions 
 
COMMENTARY 
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Background Information 
 The protocol described in this unit details how to rapidly assess the contribution of 
different pathways to steady-state ATP levels following drug or toxicant exposure in the model 
organism C. elegans. As mitochondrial function is dependent upon cellular context (Chan, 2012; 
McBride et al., 2006), this approach offers the advantage of an in vivo model, as well as all of 
the other benefits associated with working with nematodes. For example, simple RNAi gene 
knockdown technology (Kamath et al., 2003), and/or outbreeding the PE255 transgene into any 
of thousands of genetically deficient strains (Thompson et al., 2013) could extend this 
protocol’s utility to include genetic and gene-environment interaction studies. 
 Although this protocol offers many advantages over other assays capable of assessing 
mitochondrial respiratory chain health, it also has limitations. This protocol cannot distinguish 
between direct enzyme inhibition, substrate limitation, or changes in overall enzyme content as 
causative of observed changes in inhibitor based ATP-depletion. Instead, this protocol offers an 
economical way to thoroughly assess mitochondrial health that can then be followed up with 
more targeted assays, such as metabolomics, Seahorse Analysis, and gene or protein expression 
studies. Another drawback of this protocol is that it does not directly measure changes in 
steady-state ATP levels, but instead measures changes bioluminescence generated by the ATP-
powered firefly luciferase enzyme. However, targeting of mitochondrial respiratory chain genes 
by RNAi gave a bioluminescence response that correlated with steady-state ATP levels in PE255 
nematodes (Lagido et al., 2015; Lagido et al., 2008). Finally, differences in ATP depletion 
between control and exposed nematodes may be due to compensatory increases in ATP 
production via other routes, such as glycolysis. However, if this is the case then toxicant-
exposed nematodes would be expected to be less sensitive to ATP depletion induced by all ETC 
inhibitors; thus, toxicant-induced changes at only one or two of the ETC complexes is highly 
suggestive of altered function at the site of inhibition rather than a compensatory increase in 
ATP production via an alternative route.  
 In addition to the inhibitors optimized for this protocol, inhibitors of other metabolic 
pathways could also be used to further assess toxicant-induced mitochondrial dysfunction. For 
example, dichloroacetate (DCA), a pyruvate dehydrogenase kinase (negative regulator of the 
Krebs cycle) inhibitor could be used to assess changes in Krebs cycle activity. We have 
previously tested this inhibitor in the context of arsenite exposure, but observed no significant 
changes in bioluminescence under any conditions tested (1-6 hour exposure to either 0.5 or 
1.0mM DCA) (Luz et al., Submitted). Likewise, Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-
yl)ethyl sulfide (BPTES), a glutaminase (GLS1) inhibitor, could be used to test for toxicant-
induced changes in glutamine metabolism (Shukla et al., 2012). However, not all metabolic 
inhibitors will inhibit their intended targets in nematodes. For example, the mitochondrial 
uncoupler 2,4-dinitrophenol and the ATP synthase inhibitor oligomycin A do not inhibit 
mitochondrial respiration in nematodes (Luz et al., 2015a). It is probable that the nematode 
cuticle, a thick collagenous barrier, limits the uptake of these inhibitors, as oligomycin can 
inhibit mitochondrial respiration in cuticle-deficient (bus-8) nematodes (Luz et al., 2015a); thus, 
we use the less-specific ATP synthase inhibitor, DCCD, in the current protocol. 
 Finally, under certain conditions the ETC complex II inhibitor TTFA can also function as a 
mitochondrial uncoupler. However, 1mM TTFA did not increase mitochondrial respiration 
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(Supplemental Figure 13), suggesting that TTFA-induced depletion of ATP (Supplemental Figure 
3) is due to complex II inhibition. Nonetheless, we have also optimized malonate, a competitive 
inhibitor of complex II for the current protocol (Thorn, 1953). Exposure to 15mM malonate for 
one hour reduces ATP by approximately 50% (Supplemental Figure 14A), and reduces 
mitochondrial respiration (Supplemental Figure 15); however, higher concentrations of 
malonate were inexplicably found to reduce GFP fluorescence (Supplemental Figure 14B), 
which under certain conditions may confound results. Thus, we recommend researchers 
consider the caveats to working with TTFA and malonate prior to performing experiments. 
 
Critical Parameters   
Number of nematode per well 
This protocol has been optimized to work with 50 nematodes per well of a 96-well plate, and 
has successfully been used with both L4 and 8 day old adult nematodes. Fewer nematodes (25) 
have been tested, but tend to give variable luminescence values (data not shown). 
Alternatively, if this assay is to be used with L2 or L3 nematodes, the experimenter will have to 
load >50 nematodes per well, but must be careful not to overload the wells as this could result 
in anoxic conditions. 
 
Age and genetic background of nematodes 
 Early and later life stages are widely considered more sensitive to certain exposures. 
Thus, concentrations of inhibitors may need to be adjusted depending upon the life stage being 
investigated. In agreement with this, we observed increased sensitivity to ATP depletion with 
rotenone, antimycin A, and FCCP in 8 day old PE255 N2 nematodes (Figures 3-5). In contrast, 
reduced sensitivity to TTFA was observed in 8 day old PE255 N2 nematodes (Figure 6), while no 
age related sensitivities were observed for azide, DCCD, or 2-DG (Supplemental Figures 10-12). 
 Genetic deficiencies can also sensitize (or protect) an organism from toxicity following 
toxicant exposure. Therefore, if this protocol is adapted to RNAi studies or if the PE255 
transgene is crossbred into other genetically-deficient strains, inhibitor concentrations may 
need to be adjusted. However, we have crossbred the PE255 transgene into mitochondrial 
fission-deficient nematodes (drp-1), and observed similar responses to inhibitors as with PE255 
N2 nematodes (data not shown). Interestingly, young adult PE255 glp-4 nematodes appear less 
sensitive to TTFA than either L4 or 8 day old PE255 N2 nematodes, as 1mM TTFA reduced 
luminescence ~50% in glp-4 (Supplemental Figure 3) and 80-99% in N2 nematodes (Figure 6). 
On the other hand, young adult PE255 glp-4 nematodes appear more sensitive to sodium azide 
than either L4 or young adult PE255 N2, as 0.25mM azide reduced luminescence ~50% in glp-4-
deficient nematodes (Supplemental Figure 5), but did not have a statistically significant effect 
on luminescence in PE255 N2 (Supplemental Figure 10). Thus, concentrations of TTFA (500µM is 
effective for N2 versus 1000µM for glp-4) and sodium azide (500µM is effective for N2 versus 
250µM for glp-4) will need to be adjusted depending upon the genetic background. 
 
Troubleshooting  
Table 2 highlights some of the common problems encountered with this protocol, indicates 
potential causes, and outlines potential solutions to these problems. 
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Anticipated Results 
ETC Inhibitors: 
Incubation with inhibitors of the mitochondrial ETC (i.e. rotenone, TTFA, antimycin A, sodium 
azide, DCCD, FCCP) should dramatically (40-60%) reduce nematode luminescence, as these 
inhibitors directly interfere with ATP production via oxidative phosphorylation. Therefore, if 
prior toxicant exposure alters the activity of one or more ETC complexes the magnitude of ATP 
depletion will be significantly altered compared to unexposed nematodes.  For example, if 
toxicant exposure reduces complex I activity the magnitude of ATP depletion following a one-
hour incubation with rotenone will be reduced compared to unexposed nematodes. 
2-Deoxy-D-Glucose: 
 If drug or toxicant exposure increases glycolysis, then incubation with the glycolysis 
inhibitor 2-DG should reduce nematode luminescence, whereas 2-DG should have little to no 
effect on untreated nematode bioluminescence because of the relatively small baseline 
contribution of glycolysis to ATP.  
Perhexiline: 
Perhexiline, a prophylactic anti-anginal medication, prevents mitochondrial fatty acid oxidation 
(FAO) by inhibiting mitochondrial carnitine palmitoyltransferase-1 (CPT-1), thus preventing the 
transport of long chain fatty acids into mitochondria (Kennedy et al., 1996). Inhibition of FAO 
with perhexiline results in a shift in cardiac metabolism from the utilization of fatty acids to 
glucose, which is beneficial because glucose oxidation requires less oxygen per unit of ATP 
generated. Thus, perhexiline increases cardiac efficiency (Kjekshus and Mjøs, 1972; Mjos and 
Kjekshus, 1971). Like cardiac myocytes (Stanley et al., 1997), germline-deficient nematodes 
elevate fatty acid oxidation (Ratnappan et al., 2014). Thus, we hypothesized that treatment of 
PE255 glp-4-deficient nematodes with perhexiline would increase nematode luminescence by 
increasing the efficiency of ATP production, which our findings support (Supplemental Figure 8). 
In the context of toxicant exposure the effect of perhexiline on luminescence may prove more 
difficult to interpret. We postulate that toxicant exposures that disrupt glucose catabolism may 
result in increased FAO, in which case perhexiline would be expected to decrease nematode 
luminescence by inhibiting FAO. This would provide initial evidence for toxicant-induced 
changes in FAO that can be confirmed with gene expression or metabolomics studies. 
 
Time Considerations 
 It will take approximately 48 hours to culture a synchronous population of L4 PE255 
nematodes; however, the overall duration of nematode culturing will depend upon the desired 
larval stage when toxicant exposure is to be initiated. Likewise, the length of toxicant exposure 
will vary from experiment to experiment. However, following toxicant exposure the entire 
assay can be performed in approximately six hours (1.5 hours to prepare inhibitors, load 
nematodes into 96-well plates and start inhibitor exposures, and 1 - 4.5 hours of inhibitor 
exposure). 
 When performing assays inhibitors must be pipetted into the appropriate wells of the 
96-well plate in a timely manner. This is especially important for the 60 minute inhibitor 
incubation, as delays will introduce variability into the experiment. The addition of all inhibitors 
should take no more than 3-4 minutes when using a single channel pipette; however, this can 
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be further reduced by using a multi-channel pipette or by splitting samples onto multiple 96-
well plates. However, the addition of inhibitors should be staggered by 15-20 minutes if 
multiple 96-well plates are being run to ensure no overlap on the microplate reader. 
 Approximately 10-15 minutes prior to the end of the inhibitor exposure the plate reader 
can be prepped for the pending GFP and luminescence measurements. Depending upon the 
plate reader, it will take 5-10 minutes to gain adjust and measure GFP per 96-well plate. Thus to 
avoid extended incubation periods we typically begin GFP measurements 5-10 minutes before 
the end of the incubation period. This allows luminescence to be measured immediately 
following the end of the 1 or 4.5 hour incubation period, which will help limit variability 
between experiments. 
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FIGURE LEGENDS 
Figure 1. Workflow for assessing toxicant-induced mitochondrial dysfunction in luciferase 
expressing PE255 C. elegans. 
Figure 2. Example of how toxicant exposed nematodes can be loaded into a 96-well plate for 
inhibitor exposure. 
Figure 3. Eight day old PE255 N2 nematodes are more sensitive to ATP depletion following a 
one hour exposure to 20µM rotenone than 2 day old nematodes (2 way ANOVA, main effects of 
time (p=0.006), treatment (p<0.0001), and their interaction (p=0.008)). Asterisk denotes 
statistical significance (p<0.05) for post-hoc comparison (Tukey’s HSD). N=3-4. Bars±SEM. 
Figure 4. Eight day old PE255 N2 nematodes are more sensitive to ATP depletion following a 
one hour exposure to 150µM antimycin A than 2 day old nematodes (2 way ANOVA, main 
effect of treatment (p<0.0001), and time*treatment interaction (p=0.002), but not time 
(p=0.19)). Asterisk denotes statistical significance (p<0.05) for post-hoc comparison (Tukey’s 
HSD). N=3-4. Bars±SEM. 
Figure 5. Eight day old PE255 N2 nematodes are more sensitive to ATP depletion following a 
one hour exposure to 25µM FCCP than 2 day old nematodes (2 way ANOVA, main effects of 
time (p=0.02), treatment (p<0.0001), and their interaction (p=0.02)). Asterisk denotes statistical 
significance (p<0.05) for post-hoc comparison (Tukey’s HSD). N=3-4. Bars±SEM. 
Figure 6. Eight day old PE255 N2 nematodes are less sensitive to ATP depletion following a one 
hour exposure to 1mM TTFA than 2 day old nematodes (2 way ANOVA, main effects of time 
(p=0.01), treatment (p<0.0001), and their interaction (p=0.008)). Asterisk denotes statistical 
significance (p<0.05) for post-hoc comparison (Tukey’s HSD). N=3. Bars±SEM. 
Supplemental Figure 1. One hour exposure to 1% DMSO does not affect luminescence in young 
adult PE255 glp-4 nematodes compared to nematodes in EPA water control (One way ANOVA, 
p=0.65). N=4. Bars±SEM. 
Supplemental Figure 2. One hour exposure to 10, 15, and 20µM rotenone significantly reduced 
ATP compared to the 1% DMSO control in young adult PE255 glp-4 nematodes (one way 
Page 52 of 61
John Wiley & Sons
Current Protocols
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
20 
 
ANOVA, p=0.0004). 20µM Rotenone was chosen for future experiments. Asterisk denotes 
statistical significance (p<0.05) for post-hoc comparison (Tukey’s HSD) to control. N=3. 
Bars±SEM. 
Supplemental Figure 3. One hour exposure to 1mM TTFA significantly reduced ATP compared 
to the 1% DMSO control in young adult PE255 glp-4 nematodes (one way ANOVA, p=0.0005). 
1mM TTFA was used in all future experiments. Asterisk denotes statistical significance (p<0.05) 
for post-hoc comparison (Tukey’s HSD) to control. N=3. Bars±SEM. 
Supplemental Figure 4. One hour exposure to 100 and 150µM antimycin A significantly reduced 
ATP compared to the 1% DMSO control in young adult PE255 glp-4 nematodes (one way 
ANOVA, p=0.005). 150µM Antimycin A was used in all future experiments. Asterisk denotes 
statistical significance (p<0.05) for post-hoc comparison (Tukey’s HSD) to control. N=2-4. 
Bars±SEM. 
Supplemental Figure 5. One hour exposure to 0.25, 0.5, 1.0, 2.5mM sodium azide significantly 
reduced ATP compared to the EPA water control in young adult PE255 glp-4 nematodes (one 
way ANOVA, p=0.001). 0.25mM Sodium azide was used in all future experiments. Asterisk 
denotes statistical significance (p<0.05) for post-hoc comparison (Tukey’s HSD) to control. N=2-
3. Bars±SEM. 
Supplemental Figure 6. One hour exposure to 20 and 30µM DCCD significantly reduced ATP 
compared to the 1% DMSO control in young adult PE255 glp-4 nematodes (one way ANOVA, 
p=0.0002). 20µM DCCD was used in all future experiments. Asterisk denotes statistical 
significance (p<0.05) for post-hoc comparison (Tukey’s HSD) to control. N=3. Bars±SEM. 
Supplemental Figure 7. One hour exposure to 10 and 25µM FCCP significantly reduced ATP 
compared to the 1% DMSO control in young adult PE255 glp-4 nematodes (one way ANOVA, 
p=0.0008). 25µM FCCP was used in all future experiments. Asterisk denotes statistical 
significance (p<0.05) for post-hoc comparison (Tukey’s HSD) to control. N=3. Bars±SEM. 
Supplemental Figure 8. One hour exposure to 100µM perhexiline significantly increased ATP 
compared to the 1% DMSO control in young adult PE255 glp-4 nematodes (one way ANOVA, 
p=0.0061). 100µM Perhexiline was used in all future experiments. Asterisk denotes statistical 
significance (p<0.05) for post-hoc comparison (Tukey’s HSD) to control. N=3. Bars±SEM. 
Supplemental Figure 9. One hour exposure to 1% DMSO does not affect luminescence in 2 or 8 
day old PE255 N2 nematodes compared to EPA water control (two way ANOVA, main effect of 
time (p=0.0003), but not treatment (p=0.96) or their interaction (p=0.83)). N=3-7. Bars±SEM. 
Supplemental Figure 10. One hour exposure to 0.25mM sodium azide did not significantly 
affect ATP levels in 2 or 8 day old PE255 N2 nematodes compared to EPA water control (2 way 
ANOVA, main effect of time (p<0.0001), but not treatment (p=0.20) or their 
interaction(p=0.81)). N=3-4. Bars ± SEM. 
Supplemental Figure 11. One hour exposure to 20µM DCCD reduced ATP levels in 2 and 8 day 
old N2 nematodes (two way ANOVA, main effect of treatment (p=0.003), but not time (p=0.33) 
or their interaction (p=0.38)). N=3-7. Bars±SEM. 
Supplemental Figure 12. Four and a half hours exposure to 50mM 2-DG did not significantly 
affect ATP levels in 2 or 8 day old PE255 N2 nematodes compared to EPA water control (2 way 
ANOVA, main effect of time (p<0.0001), but not treatment (p=0.56) or their interaction 
(p=0.70)). N=3. Bars ± SEM. 
Page 53 of 61
John Wiley & Sons
Current Protocols
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
21 
 
Supplemental Figure 13. Exposure to 1mM TTFA did not affect mitochondrial respiration in 
young adult PE255 glp-4 nematodes (one way ANOVA, p=0.53). N=7-22. Bars ± SEM. 
Supplemental Figure 14. One hour exposure to malonate significantly reduced (A) ATP levels 
(one way ANOVA, p<0.0001) and (B) GFP fluorescence (one way ANOVA, p=0.014) in young 
adult PE255 glp-4 nematodes. Asterisk denotes statistical significance (p<0.05) for post-hoc 
comparison (Tukey’s HSD) to control. N=3. Bars ± SEM. 
Supplemental Figure 15. Exposure to malonate reduced mitochondrial respiration in young 
adult PE255 glp-4 nematodes (one way ANOVA, p<0.0001). Asterisk denotes statistical 
significance (p<0.05) for post-hoc comparison (Tukey’s HSD) to control. N=4-12. Bars ± SEM. 
TABLES 
Table 1. Preparation of Inhibitors 
 
Inhibitor           
(Target) 
Stock 
Concentration 
Working Concentration 
(8x) 
Final 
Concentration 
(1x) 
Incubation 
period (Hours) 
Rotenone       
(ETC Complex I) 
2mM dissolved 
in 100% DMSO 
(store at -20°C 
in 30µl aliquots) 
160µM Dissolved in 8% 
DMSO                                       
To make: Add 24µl 
2mM Rotenone (100% 
DMSO) to 276µl 
unbuffered EPA H2O 
20µM in 1% 
DMSO 
1 
*TTFA                
(ETC Complex II) 
 
 
 
 
¥
Malonate  
(ETC Complex II) 
100mM 
dissolved in 
100% DMSO 
(store at 4°C in 
30µl aliquots) 
 
120mM 
dissolved in 
100% 
unbuffered EPA 
H2O (store at 
4°C in 1mL 
aliquots)  
8mM Dissolved in 8% 
DMSO  
To make: Add 24µl 
100mM TTFA to 276µl 
unbuffered EPA H2O 
 
120mM dissolved in 
100% unbuffered EPA 
H2O 
1mM in 1% 
DMSO 
 
 
 
 
15mM in 100% 
unbuffered 
EPA H2O 
1 
 
 
 
 
 
1 
Antimycin A   
(ETC Complex III)  
15mM 
dissolved in 
100% DMSO 
(store at -20°C 
in 30µl aliquots) 
1.2mM Dissolved in 8% 
DMSO 
To make: Add 24µl 
15mM Antimycin A 
(100% DMSO) to 276µl 
unbuffered EPA H2O 
150µM in 1% 
DMSO  
1 
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**Sodium Azide 
(ETC Complex IV) 
2mM dissolved 
in 100% 
unbuffered EPA 
H2O (store at 
4°C in 1mL 
aliquots) 
2mM dissolved in 100% 
unbuffered EPA H2O 
250µM in 
100% 
unbuffered 
EPA H2O 
1 
DCCD               
(ATP synthase) 
2mM dissolved 
in 100% DMSO 
(store at -20°C 
in 30µl aliquots) 
160µM Dissolved in 8% 
DMSO                                       
To make: Add 24µl 
2mM DCCD (100% 
DMSO) to 276µl 
unbuffered EPA H2O 
20µM in 1% 
DMSO 
1 
FCCP 
(Mitochondrial 
uncoupler) 
2.5mM 
dissolved in 
100% DMSO 
(store at -20°C 
in 30µl aliquots) 
200µM Dissolved in 8% 
DMSO                                       
To make: Add 24µl 
2.5mM FCCP (100% 
DMSO) to 276µl 
unbuffered EPA H2O 
25µM in 1% 
DMSO 
1 
Perhexiline  
(Fatty acid 
oxidation) 
10mM 
dissolved in 
100% DMSO 
(store at 4°C in 
30µl aliquots) 
800µM Dissolved in 8% 
DMSO                                       
To make: Add 24µl 
10mM Perhexiline 
(100% DMSO) to 276µl 
unbuffered EPA H2O 
100µM in 1% 
DMSO 
1 
2-DG     
(Glycolysis) 
400mM 
dissolved in 
unbuffered EPA 
H2O (store at 
4°C in 30 µl 
aliquots) 
400mM dissolved in 
unbuffered EPA H2O 
50mM in 100% 
unbuffered 
EPA H2O  
4.5 
Concentrations of ETC inhibitors listed in Table 1 caused roughly a 40-60% reduction in 
bioluminescence in young adult PE255 glp-4 deficient nematodes (Supplemental Figures 2-7), and 
with the exceptions of TTFA and sodium azide, cause similar reductions in both L4 and 8 day old 
PE255 N2 nematodes. 
*500µM TTFA reduces luminescence approximately 50% in PE255 N2 nematodes (data not shown), 
while 1000µM causes an 80-99% reduction in PE255 N2 bioluminescence (Figure 6). 
**250µM Sodium azide has no significant effect on PE255 N2 bioluminescence, while 500µM azide 
reduces bioluminescence ~50%. 
¥ Malonate, a competitive inhibitors of ETC complex II, can be used in place of TTFA at the 
discretion of the experimenter. Pros and cons of this are discussed in the Background Information 
section. 
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TABLE 2. Trouble Shooting 
Problem Possible cause Solution 
Inhibitor caused no, or only a 
minor decrease in 
luminescence 
Concentration of inhibitor is 
too low. 
 
Inhibitor precipitated out of 
solution 
 
 
 
 
 
 
 
Luminescence optic not 
installed properly 
 
 
Luciferin was not added to the 
luminescence buffer. 
 
 
Luminescence buffer failed to 
inject 
Increase inhibitor 
concentration. 
 
It is imperative that inhibitor 
stocks equilibrate to room 
temperature prior to their 
addition to the white 96-well 
plates, as the rapid 
temperature change may cause 
the inhibitors to precipitate out 
of solution.  
 
Check that the luminescence 
optic has been installed 
properly. 
 
Re-prepare the luminescence 
buffer taking care to add 
luciferin to the buffer. 
 
Ensure that your plate reader’s 
injector needle has been 
properly installed and/or that 
luminescence buffer was 
properly added prior to 
measuring luminescence. 
Inhibitor resulted in greater 
than a 90% loss of 
luminescence. 
Inhibitor concentration is too 
high. 
Decrease the concentration of 
inhibitor used.  
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